Literature DB >> 20956983

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Paula Cramer1, Michael Hallek.   

Abstract

Of all leukemias, chronic lymphocytic leukemia (CLL) shows the highest variability in its clinical presentation and course. CLL can present as an aggressive and life threatening leukemia or as an indolent form that will not require treatment over decades. The currently available clinical staging systems for CLL are simple and inexpensive but lack accuracy to predict disease progression and survival on an individual basis. The increased understanding of the key events of molecular pathogenesis has provided a plethora of novel molecular and biological factors that correlate with the outcome of CLL. This Review provides a concise discussion of the most important discoveries and gives guidance on how to implement novel prognostic tools in the clinical management of CLL by applying the criteria of evidence, relevance, and simplicity to the selection of prognostic markers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956983     DOI: 10.1038/nrclinonc.2010.167

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  123 in total

1.  Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

Authors:  D F Jelinek; R C Tschumper; S M Geyer; N D Bone; G W Dewald; C A Hanson; M J Stenson; T E Witzig; A Tefferi; N E Kay
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

2.  Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages.

Authors:  Massimo Gentile; Giovanna Cutrona; Antonino Neri; Stefano Molica; Manlio Ferrarini; Fortunato Morabito
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

4.  Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Authors:  G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

Review 5.  Sex differences in incidence and outcome of chronic lymphocytic leukemia patients.

Authors:  Stefano Molica
Journal:  Leuk Lymphoma       Date:  2006-08

6.  Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Authors:  Marco Montillo; Alessandra Tedeschi; Sara Miqueleiz; Silvio Veronese; Roberto Cairoli; Liliana Intropido; Francesca Ricci; Anna Colosimo; Barbara Scarpati; Michela Montagna; Michele Nichelatti; Mario Regazzi; Enrica Morra
Journal:  J Clin Oncol       Date:  2006-04-17       Impact factor: 44.544

Review 7.  Predicting clinical outcome in CLL: how and why.

Authors:  Tait D Shanafelt
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases.

Authors:  C Rozman; E Montserrat; J M Rodríguez-Fernández; R Ayats; T Vallespí; R Parody; A Ríos; D Prados; M Morey; F Gomis
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

Review 9.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

10.  Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.

Authors:  S Molica; A Alberti
Journal:  Cancer       Date:  1987-12-01       Impact factor: 6.860

View more
  56 in total

1.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

Review 2.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

3.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

Review 4.  On the architecture of translational research designed to control chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.

Authors:  Barbara L Andersen; Neha Godiwala Goyal; David M Weiss; Travis D Westbrook; Kami J Maddocks; John C Byrd; Amy J Johnson
Journal:  Cancer       Date:  2018-05-14       Impact factor: 6.860

6.  FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Hun Ju Lee; Wei Qiao; William Wierda; Ohad Benjamini; Jan Burger; Alessandra Ferrajoli; Zeev Estrov; Hagop Kantarjian; Michael Keating; Susan O'Brien
Journal:  Cancer       Date:  2014-07-15       Impact factor: 6.860

Review 7.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

Review 8.  Management of chronic lymphocytic leukemia.

Authors:  Paolo Ghia; Michael Hallek
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

9.  Prognostic factors in CLL.

Authors:  M Ferrarini; G Cutrona; A Neri; F Morabito
Journal:  Leuk Suppl       Date:  2012-08-09

10.  The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1.

Authors:  D Rossi; S Rasi; V Spina; A Bruscaggin; S Monti; S Cresta; R Famà; C Deambrogi; M Greco; M Fangazio; C Ciardullo; D Piranda; G M Casaluci; M Messina; I D Giudice; S Chiaretti; M Marinelli; A Guarini; R Foà; G Gaidano
Journal:  Leuk Suppl       Date:  2012-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.